- |||||||||| Yutuo (zimberelimab) / Arcus Biosci, Gilead, ralzapastotug (AB308) / Arcus Biosci, Gilead
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (clinicaltrials.gov) - May 29, 2024
P1, N=94, Active, not recruiting,
Trial completion date: Jan 2025 --> Sep 2025 | Trial primary completion date: Jan 2025 --> Sep 2025
- |||||||||| Yutuo (zimberelimab) / Arcus Biosci, Gilead, ralzapastotug (AB308) / Arcus Biosci, Gilead
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (clinicaltrials.gov) - Feb 15, 2024
P1, N=94, Active, not recruiting,
Trial completion date: Jan 2025 --> Sep 2025 | Trial primary completion date: Jan 2025 --> Sep 2025 Trial completion date: Jan 2024 --> Mar 2025 | Trial primary completion date: Jan 2024 --> Mar 2025
- |||||||||| ralzapastotug (AB308) / Arcus Biosci, Gilead, Otsuka
Fc-silent anti-TIGIT antibodies potentiate anti-tumor immunity without depleting regulatory T cells (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_831;
P1
Anecdotal clinical outcomes in two patients from NCT03628677 receiving domvanalimab in combination with an anti-PD-1 antibody, zimberelimab, are also reported...Conclusions We demonstrate that Fc-silent anti-TIGIT antibodies potentiate activation of tumor-specific T cells and anti-tumor efficacy without depleting Treg (figure 1). These data provide critical insights related to activity of anti-TIGIT antibodies lacking Fc functionality, such as domvanalimab.
- |||||||||| Yutuo (zimberelimab) / Arcus Biosci, Gilead, ralzapastotug (AB308) / Arcus Biosci, Gilead
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (clinicaltrials.gov) - Sep 1, 2023
P1, N=94, Active, not recruiting,
These data provide critical insights related to activity of anti-TIGIT antibodies lacking Fc functionality, such as domvanalimab. Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Jan 2024 | Trial primary completion date: Jul 2025 --> Jan 2024
- |||||||||| Yutuo (zimberelimab) / Arcus Biosci, Gilead, ralzapastotug (AB308) / Arcus Biosci, Gilead
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (clinicaltrials.gov) - Jun 9, 2023
P1, N=107, Recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Jan 2024 | Trial primary completion date: Jul 2025 --> Jan 2024 Trial completion date: Dec 2023 --> Jul 2025 | Trial primary completion date: Jun 2023 --> Jul 2025
- |||||||||| AB308 / Arcus Biosci, Gilead, Otsuka
Anti-TIGIT antibodies promote immune activation relevant to targeting stem-like and tumor-specific T cells in combination with anti-PD-1 (Exhibit Hall; P950) - Apr 8, 2022 - Abstract #IMMUNOLOGY2022IMMUNOLOGY_1910;
In mice, while combining Fc-silent or Fc-enabled anti-mouse TIGIT antibody with anti-PD-1 resulted in greater tumor growth inhibition than with anti-PD-1 alone, the activity of Fc-enabled anti-TIGIT was associated with intratumoral Treg depletion. These data provide a rationale for combination with immune-activating agents and support ongoing clinical evaluation of AB154 and AB308 with biomarker strategies focused on understanding the role of Fc functionality.
|
